Treating cutaneou leishmaniasis patients in Kabul, Afghanistan: Cost-effectiveness of an operational program in a complex emergency setting

BMC Infectious Diseases

Volumn 7, Issue , 2007, Pages

  Reithinger, Richard ^a,b,c   Coleman, Paul G ^b  

^a Clinical Trials Area   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Malaria and Leishmaniasis   (Afghanistan)

Author keywords

[No Author keywords available]

Indexed keywords

STIBOGLUCONATE SODIUM;

AFGHANISTAN; ARTICLE; CALCULATION; CITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; EMERGENCY; HEALTH CARE COST; HUMAN; INCIDENCE; PROBABILITY; SENSITIVITY ANALYSIS; SKIN LEISHMANIASIS; STATISTICAL MODEL; ALTERNATIVE MEDICINE; COST BENEFIT ANALYSIS; HEALTH CARE POLICY;

AFGHANISTAN; COMPLEMENTARY THERAPIES; COST-BENEFIT ANALYSIS; EMERGENCIES; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; LEISHMANIASIS, CUTANEOUS;

EID: 33846950803     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-7-3     Document Type: Article

References (40)

1. World Health Organization The World Health Report. Changing History World Health Organization, Geneva 2004 1 96 http://www.who.int/entity/ whr/2004/en/report04_en.pdf Accessed November 13, 2006.
2. Reithinger R Mohsen M Aadil K Sidiqi M Erasmus P Coleman PG Anthroponotic cutaneous leishmaniasis, Kabul, Afghanistan Emerg Infect Dis 2003 9 727-9 12781016
3. Reithinger R Aadil K Kolaczinski J Mohsen M Hami S Social impact of leishmaniasis, Afghanistan Emerg Infect Dis 2005 11 634-6 15834984
4. Ashford RW Kohestany KA Karimzad MA Cutaneous leishmaniasis in Kabul: observations on a 'prolonged epidemic' Ann Trop Med Parasitol 1992 86 361-71 1463356
5. UN Office for Coordination of Humanitarian Affairs Financial Tracking Service - Tracking global humanitarian aid flows http://ocha.unog.ch/fts/ index.aspx accessed November 13, 2006
6. Walker P Wisner B Leaning J Minear L Smoke and mirrors: Deficiencies in disaster funding BMJ 2005 29 247-50 10.1136/bmj.330.7485.247
7. Murray CJL Lopez AD The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020 Harvard University Press 1996
8. United Nations Development Program Afghanistan National Human Development Report 2004: Security with a human face - challenges and responsibilities United Nations Development Program, Islamabad 2004 1 316
9. Waldmann R Hanif H Afghanistan Research Evaluation Unit. Issues Paper Series. The Public Health System in Afghanistan - Current Issues The Afghanistan Research Evaluation Unit, Islamabad 2002 1-46
10. Meddings DR Ronald LA Marion S Pinera JF Oppliger A Cost-effectiveness of a latrine revision program in Kabul, Afghanistan Bull WHO 2004 82 281-89 15259257
11. Anonymous WHO action in Afghanistan aims to control debilitating leishmaniasis Wkly Epidemiol Rec 2004 79 319-20 15382405
12. Reyburn H A Guide to the treatment of cutaneous leishmaniasis World Health Organization, Kabul 2000
13. Herwaldt BL Leishmaniasis Lancet 1999 354 1191-9 10.1016/ S0140-6736(98)10178-2 10513726
14. Johns B Baltussen R Hutubessy R Program costs in the economic evaluation of program costs Cost Effectiveness and Resource Allocation 2003 1 1 10.1186/1478-7547-1-1
15. Lopez AD Mathers CD Ezzati M Jamison DT Murray CJL Global Burden if Disease and Risk Factors The World Bank and Oxford University Press 2006 1-475
16. Barendregt JJ Bonneux L Van der Maas PJ DALYs: The age-weights on balance Bull WHO 1996 74 439-43 8823967
17. Reithinger R Mohsen M Wahid M Bismullah M Quinnell RJ Davies CR Kolaczinski J David JR Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: A randomized, controlled trial Clin Infect Dis 2005 40 1148-55 10.1086/ 428736 15791515
18. Tallab TM Bahamdam KA Mirdad S Johargi H Mourad MM Ibrahim K el Sherbini AH Karkashan E Khare AK Jamal A Cutaneous leishmaniasis: Schedules for intralesional treatment with sodium stibogluconate Int J Dermatol 1996 35 594-7 8854166
19. Asilian A Sadeghinia A Faghihi G Momeni A Amini Harandi A The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis Ann Trop Med Parasitol 2003 97 493-8 10.1179/ 000349803225001373 12930612
20. Ballou WR McClain JB Gordon DM Shanks GD Andujar J Berman JD Chulay JD Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis Lancet 1987 2 13-6 10.1016/ S0140-6736(87)93053-4 2885505
21. Martinez S Marr JJ Allopurinol in the treatment of American cutaneous leishmaniasis N Engl J Med 1992 326 741-4 1738379
22. Goodman CA Coleman PG Mills AJ Cost-effectiveness of malaria control in sub-Saharan Africa Lancet 1999 354 378-385 10.1016/S0140-6736(99)02141-8 10437867
23. Banatvala N Zwi AB Conflict and health: Public health and humanitarian interventions: Developing the evidence base BMJ 2000 321 101-5 1127723 10884265 10.1136/bmj.321.7253.101
24. Duffield A Reid G Shoham J Walker D Evidence base for interventions in complex emergencies Lancet 2005 365 842-3 10.1016/S0140-6736(05)71034-5 15752520
25. Connolly MA Gayer M Ryan MJ Salama P Spiegel P Heymann DL Communicable disease in complex emergencies: Impact and challenges Lancet 2004 364 1974-83 10.1016/S0140-6736(04)17481-3 15567014
26. Arana BA Mendoza CE Rizzo NR Kroeger A Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala Am J Trop Med Hyg 2001 65 466-70 11716099
27. Guthmann JP Arlt D Garcia LM Rosales M de Jesus Sanchez J Alvarez E Lonlas S Conte M Bertoletti G Fournier C Huari R Torreele E Llanos-Cuentas A Control of mucocutaneous leishmaniasis, a neglected disease: Results of a control program in Satipo Province, Peru Trop Med Int Health 2005 10 856-62 10.1111/j.1365-3156.2005.01460.x 16135192
28. Tan-Torres Edejer T Baltussen R Adam T Hutubessy R Acharya A Evans DB Murray CJL WHO Guide to Cost-effectiveness Analysis World Health Organization, Geneva 2003 1-329
29. US Department of State Background Note Afghanistan Profile http://www.state.gov/r/pa/ei/bgn/5380.htm Accessed November 13, 2006.
30. Griffiths UK Wolfson LJ Quddus A Younus M Hafiz RA Incremental cost-effectiveness of supplementary immunization activities to prevent neonatal tetanus in Pakistan Bull WHO 2004 82 643-51 15628201
31. Politi C Carrin G Evans D Kuzoe FA Cattand PD Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda Health Econ 1995 4 273-87 8528430
32. Griekspoor A Sondorp E Vos T Cost-effectiveness analysis of humanitarian relief interventions: Visceral leishmaniasis treatment in the Sudan Health Policy and Planning 1999 14 70-78 10.1093/heapol/14.1.70
33. Waters HR Rehwinkel JA Burnham G Economic evaluation of Mectizan distribution Trop Med Int Healt 2004 9 A16-25 10.1111/ j.1365-3156.2004.01210.x
34. Varley RC Tarvid J Chao DN A reassessment of the cost-effectiveness of water and sanitation interventions in programs for controlling childhood diarrhea Bull WHO 1998 76 617-31 10191558
35. Baltussen RM Sylla M Frick KD Mariotti SP Cost-effectiveness of trachoma control in seven world regions Ophthalmic Epidemiol 2005 12 91-101 10.1080/09286580590932761 16019692
36. King CH Dickman K Tisch DJ Reassessment of the cost of chronic helminthic infection: A meta-analysis of disability-related outcomes in endemic schistosomiasis Lancet 2005 365 1561-9 10.1016/ S0140-6736(05)66457-4 15866310
37. Arnesen T Kapiriri L Can the value choices in DALYs influence global priority-setting? Health Policy 2004 70 137-49 10.1016/ j.healthpol.2003.08.004 15364144
38. Handman E Leishmaniasis: Current status of vaccine development Clin Microbiol Rev 2001 14 229-43 88972 11292637 10.1128/CMR.14.2.229-243.2001
39. Thieren M Health information systems in humanitarian emergencies Bull WHO 2005 83 584-9 16184277
40. Kapiriri L Arnesen T Norheim OF Is cost-effectiveness analysis preferred to severity of disease as the main guiding principle in priority setting in resource poor settings? The case of Uganda Cost Eff Resour Alloc 2004 2 1 324572 14711374 10.1186/1478-7547-2-1